SEC 13F Intelligence

Farallon Capital Management, L.L.C. / 260

Farallon Capital Management, L.L.C.’s Centessa Pharmaceuticals PLC Position

Does Farallon Capital Management, L.L.C. own Centessa Pharmaceuticals PLC (260)? Yes — 4.81M shares worth $191M (+1.04% of its 13F portfolio) as of Q1 2026, down from 5.38M shares the prior filed quarter.

Position Value
$191M
Q1 2026
Shares
4.81M
% of Portfolio
+1.04%
Quarters Held
9
currently held

Position History 260

Reported value by quarter
Q1 ’24: $4MQ1 ’24Q2 ’24: $18MQ3 ’24: $45MQ3 ’24Q4 ’24: $59MQ1 ’25: $62MQ1 ’25Q2 ’25: $60MQ3 ’25: $105MQ3 ’25Q4 ’25: $134MQ1 ’26: $191MQ1 ’26filingsflow.com
QuarterSharesValue% of Portfolio
Q1 20264.81M$191M+1.04%
Q4 20255.38M$134M+0.63%
Q3 20254.33M$105M+0.43%
Q2 20254.53M$60M+0.25%
Q1 20254.33M$62M+0.33%
Q4 20243.50M$59M+0.30%
Q3 20242.81M$45M+0.22%
Q2 20242.00M$18M+0.08%
Q1 2024371.0K$4M+0.02%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Farallon Capital Management, L.L.C.’s full portfolio or all institutional holders of 260.